The deaths from cancer and heart disease are the leading causes of mortality for more than 35 years in Taiwan. This project intends to explore the incidences of cardiovascular disease (CVD), myocardial infarction (MI) and cancer in those who suffering from inflammatory diseases (ID), receiving medical treatment and carrying genetic variants of significantly related to ID. As we know, there were many clinical evidences showed that those with cancer, atherosclerosis or CVD always correlated with chronic inflammation at sites of tumor or artery walls; moreover, inflammation syndrome also associated with different genetic variants in those with specific cancers or different ethnic population. Thus, we are interested in the interaction effects of genetic variants and medication on the incidences of CVD/MI/Cancer.
We will perform this project for a duration of three years. During this period, we will analysis UK biobank to explore genetic variants of related to inflammatory diseases (ID) at first. And then, we will use the Taiwan biobank as replication cohort. The analysis of replication cohort is the same as UK biobank done. All IDs will be the outcome variable in this step. This step can explore the genetic variants significantly related to IDs, the variants may appear in both cohorts or only in one cohort. According to the results got from the above, different approach for explore the incidences of CVD/MI/Cancer will be performed.
The next step is to link the participants of Taiwan biobank who were identified as ID and without CVD/MI/cancer to National Health Insurance Research Database in Taiwan (NHIRD). NHIRD which provides each participants medical records. The link procedure will also be grouped in different combinations of between genetic variants and ID treatment medication. This will explore the CVD/MI/Cancer incidence according to different interactions of between genetic variants and medication of IDs.
We expect to find many kinds combinations of inflammatory medication and related genetic variants, and we hope this study can explore the interaction effects of between genetic variants and medication related to inflammatory diseases on the incidence of CVD/MI/Cancer. The results can be applied to personal medical treatment for inflammatory diseases to avoid CVD/MI/Cancer occurrence, and that can reduce much mortality, morbidity from MI/Cancer and medical costs. Moreover, nowadays is a genetic next-generation age, the results are important for the precision medicine for public health.